Stay updated on IO Combo After Radiation in Esophagogastric Cancer Clinical Trial
Sign up to get notified when there's something new on the IO Combo After Radiation in Esophagogastric Cancer Clinical Trial page.
Latest updates to the IO Combo After Radiation in Esophagogastric Cancer Clinical Trial page
- Check3 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe website has been updated to version v2.13.3, with new additions including dates in December 2024 and a revision, while the previous version v2.13.2 and several dates from September 2024 have been removed.SummaryDifference0.4%
- Check39 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, while removing the previous wording about those conducting the study.SummaryDifference1%
- Check53 days agoChange DetectedSeveral links to PubMed articles and resources related to Nivolumab and Relatlimab have been removed, along with various study-related data fields and options for downloading study information.SummaryDifference3%
- Check61 days agoChange DetectedThe website has been updated to version 2.12.2, adding numerous PubMed links related to Nivolumab and Relatlimab, as well as new data fields for study information, while removing the previous version 2.12.1.SummaryDifference3%
- Check75 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.0%
Stay in the know with updates to IO Combo After Radiation in Esophagogastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO Combo After Radiation in Esophagogastric Cancer Clinical Trial page.